Update on the treatment of childhood-onset autoimmune hemolytic anemias
10.3760/cma.j.issn.1673-4408.2021.01.013
- VernacularTitle:儿童自身免疫性溶血性贫血治疗进展
- Author:
Yi MENG
;
Yubin WU
- From:
International Journal of Pediatrics
2021;48(1):52-55
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune hemolytic anemia is a disorder of immune function caused by various reasons, by produceing autoantibody or complement which can react with erythrocyte autoantigen, increasing the destruction of red blood cell and beyond the compensatory ability of bone marrow hematopoiesis.Children usually have acute onset and the clinical manifestations are related to the pathogenesis.As the first-line treatment of glucocorticoids, Most children respond well to glucocorticoids.Some children suffer from steroid dependence and resistance; or recurrence due to different types of antibodies, often requiring second-line treatment, such as splenectomy, immunosuppressive, etc.This article reviews the recent progress in the treatment of children with autoimmune hemolytic anemia.
